Decline of chaperone-mediated autophagy in aging impairs macrophage clearance of senescent cells.
Key claim: Age-related decline of chaperone-mediated autophagy impairs macrophage clearance of senescent cells, and pharmacological CMA activation reduces senescent-cell burden in aged mice.
Abstract
Autophagy dysfunction and senescence are established drivers of aging, but their potential interaction remains poorly understood. Here we show that age-related decline of chaperone-mediated autophagy (CMA), a pathway for selective lysosomal protein degradation, changes senescent cell properties and impairs their immune clearance. CMA-deficient cells undergo senescence but acquire proteomic, metabolic and secretory features resembling those in aged senescent cells. Their senescence-associated secretory phenotype exhibits enhanced pro-senescence effects on neighboring cells and inhibits macrophage CMA, which impairs their ability to engulf senescent cells. Accordingly, blockage of CMA specifically in macrophages increases senescent cell accumulation in mice and delays senescence resolution during wound healing. Conversely, pharmacological CMA activation reduces senescent cell burden in aged mice and disease severity in a pulmonary fibrosis mouse model. Our findings identify CMA decline as a driver of senescent cell persistence and highlight CMA upregulation as a promising strategy to promote senescence resolution in aged organisms.
Why this matters
Chaperone-mediated autophagy had been a plausible but loosely connected proteostasis node in the aging picture; this work pins it to a concrete functional lesion — aged macrophages failing to clear senescent cells — and shows pharmacologic CMA activation reduces senescent burden in aged mice and in a fibrosis model. That reframes CMA as an upstream lever simultaneously acting on SASP composition and on the immune-clearance arm, overlapping territory the field has mostly carved up between direct senolytics and immune-checkpoint (PD-L2) approaches. Evidence remains preclinical, with no human translation of a CMA activator yet.